Results 101 to 110 of about 24,724 (196)

A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation

Scientific Reports
The search for new approaches in cancer therapy requires a mechanistic understanding of cancer vulnerabilities and anti-cancer drug mechanisms of action.
Alex Y. Ge, Abolfazl Arab, Raymond Dai, Albertas Navickas, Lisa Fish, Kristle Garcia, Hosseinali Asgharian, Jackson Goudreau, Sean Lee, Kathryn Keenan, Melissa B. Pappalardi, Michael T. McCabe, Laralynne Przybyla, Hani Goodarzi, Luke A. Gilbert   +14 more
doaj   +1 more source

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

, 2016
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +2 more sources

Serendipity: Decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia [PDF]

, 2019
Abboud, Camille N, Abboud, Ramzi, Cashen, Amanda F, DiPersio, John F, Duncavage, Eric J, Han, Se Young, Shirai, Cara Lunn, Welch, John S   +7 more
core   +3 more sources

Economic Burden of Intravenous Decitabine Administration in Patients Affected by Acute Myeloid Leukemia Ineligible for Induction Chemotherapy and Impact of Oral Formulation Introduction: A Micro-Costing Study in Italy

ClinicoEconomics and Outcomes Research
Alessandra Di Costanzo, Luca Loreto, Chiara Vassallo, Francesca Fiorentino Real World Solutions, IQVIA Solutions Italy S.r.l., Milan, ItalyCorrespondence: Chiara Vassallo, Real World Solutions, IQVIA Solutions Italy s.r.l., Via Fabio Filzi 29, Milan ...
Di Costanzo A, Loreto L, Vassallo C, Fiorentino F   +3 more
doaj  

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen [PDF]

, 2017
Abboud, Camille N, Ali, Alaa M, Cashen, Amanda F, DiPersio, John F, Fehniger, Todd A, Gao, Feng, Ghobadi, Armin, Jacoby, Meagan A, Oh, Stephen T, Pusic, Iskra, Romee, Rizwan, Schroeder, Mark A, Stockerl-Goldstein, Keith E, Uy, Geoffrey L, Vij, Ravi, Wartman, Lukas D, Weisel, Daniel, Welch, John S, Westervelt, Peter   +18 more
core   +2 more sources

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

Journal of Blood Medicine, 2015
Christopher Arthur,1 Jaroslav Cermak,2 Jacques Delaunay,3 Jirí Mayer,4 Grzegorz Mazur,5 Xavier Thomas,6 Agnieszka Wierzbowska,7 Mark M Jones,8 Erhan Berrak,8 Hagop Kantarjian9 1Department of Haematology, Royal North Shore Hospital, Sydney, NSW ...
Arthur C, Cermak J, Delaunay J, Mayer J, Mazur G, Thomas X, Wierzbowska A, Jones MM, Berrak E, Kantarjian H   +9 more
doaj  

Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes

Терапевтический архив, 2013
AIM: To estimate a change in myelodysplasia in decitabine-treated patients with myelodysplastic syndromes (MDS)/MATERIAL AND METHODS: Thirteen MDS patients from a high-risk group were examined; 75 bone marrow puncture specimens and 67 bone marrow ...
V N Dvirnyk, A V Kokhno, E N Glasko, É G Gemdzhian, O A Diagileva, T L Platonova, E N Parovichnikova   +6 more
doaj  

Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability. [PDF]

Cancer Res Commun
Anabtawi N, Drabison T, Ham AF, Boeckman M, Stromatt JC, Orwick SJ, Buelow DR, Kaur T, Ahmed EA, Eisenmann ED, Govindarajan R, Sparreboom A, Baker SD.   +12 more
europepmc   +1 more source

Low-dose decitabine increases peripheral NKT-like cell proportions in patients with chronic myeloid neoplasms. [PDF]

Cancer Pathog Ther
Zhang Z, Wang Y, Zhang H, Zhao J, Yang Z, Wang X, Tang Y, Lu X, Xu R.   +8 more
europepmc   +1 more source

Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report. [PDF]

Ann Hematol
Geissler K, Mitterbauer-Hohendanner G, Jäger R.   +2 more
europepmc   +1 more source